NDAORALTABLET
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
6/8 — Strong
EVOTAZ (atazanavir and cobicistat) by Bristol Myers Squibb is cytochrome p450 3a inhibitors [moa]. First approved in 2015.
Drug data last refreshed 33m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVOTAZ is a fixed-dose combination of atazanavir (an HIV protease inhibitor) and cobicistat (a cytochrome P450 3A inhibitor that boosts atazanavir levels) administered orally as a tablet. It is indicated for treatment of HIV-1 infection in antiretroviral-experienced and treatment-naïve adults. The drug works by inhibiting viral protease and enhancing the pharmacokinetics of the active antiretroviral agent.
$12MPart D
PeakDeclining
5.9 years to LOEThe product is in peak lifecycle stage with modest Part D spending; declining claims suggest erosion as alternative regimens gain market share, signaling smaller brand team and transition planning needs.
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions
Started May 2022
42 enrolled
Healthy Participants
A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time
Started Feb 2020
34 enrolled
Healthy Participants
Pharmacokinetic Effect of Evotaz/Microgynon Co-administration
Started Jul 2016
13 enrolled
HIV
Taste Properties of Atazanavir and Cobicistat
Started Dec 2014
6 enrolled
HIV in Adults
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
Started Apr 2013
64 enrolled
Human Immunodeficiency Virus Type 1 (HIV-1)
Worked on EVOTAZ at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.